Lung Cancer Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• 24: Lung cancer as an 'acute presentation' in acute unselected medical admissions at a district general hospital (audit at Kings Mill hospital, November 2013–May 2014) 2015
• E22. Reimbursement policies, research andprescribing practices: The Canadian perspective 2005
• Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed plus cisplatin versus cisplatin trial 2005
• Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM) 2005
• P-126 Activation of tyrosine kinase receptors and intracellular signal mediators in NSCLC tumors 2005
• P-252 Interim report: A phase III randomized double blindchemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer 2005
• P-936 Use of an algorithm to aid determination of causality in early clinical trials of lung cancer using targeted therapy 2005
• Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC) 2005
• Reporting on consistency of clinical practice with lung cancer guidelines: A clinical monograph by Cancer Care Ontario 2005
• Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model 2005
• Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study 2005
• A study examining epidermal growth factor receptor, p53, and Bcl-2 expression in patients with locally advanced squamous cell carcinoma of the head and neck treated with concomitant chemoradiotherapy 2004
• Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.  194:107898-107898. 2024
• ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.  161:9-17. 2021
• Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.  160:127-135. 2021
• The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.  160:136-151. 2021
• Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.  157:40-47. 2021
• A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”.  151:110-111. 2021
• Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.  151:108-109. 2021
• A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.  143:1-11. 2020
• Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.  139:185-194. 2020
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.  134:259-267. 2019
• Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.  133:48-55. 2019
• Ultrasonographic characteristics of lymph nodes as predictors of malignancy during endobronchial ultrasound (EBUS): A systematic review.  126:97-105. 2018
• Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.  120:142-148. 2018
• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.  104:65-69. 2017
• Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness.  101:98-103. 2016
• Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.  99:180-185. 2016
• Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study.  90:8-14. 2015
• MicroRNA expression profiling of thymic epithelial tumors.  85:197-204. 2014
• Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).  82:115-120. 2013
• A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.  74:481-485. 2011
• The function of IGF-IR in NNK-mediated lung tumorigenesis.  71:11-18. 2011
• Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.  52:327-332. 2006
• Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline.  50:355-374. 2005
• P-125 p-38 MAPK, Erk and Akt expression and activation in NSCLCtumors; Subcellular distribution and radiographic response to radiotherapy.  49:S147-S148. 2005
• P-401 Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed + cisplatin versus cisplatin trial.  49:S220-S221. 2005
• P-422 Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study.  49:S226-S226. 2005
• P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model.  49:S229-S229. 2005
• P-435 Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM).  49:S230-S231. 2005
• P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC).  49:S255-S256. 2005
• PD-118 High dose rate endobronchial brachytherapy (HDREB) in the palliation of patients with non-small cell lung cancer (NSCLC): A systematic review.  49:S101-S102. 2005
• Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.  48:157-169. 2005
• Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.  48:47-57. 2005
• Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary?.  46:379-380. 2004
• Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.  46:361-368. 2004
• Response to issues raised by Dr. Debevec ?Is postoperative radiotherapy for radically resected NSCLC detrimental and therefore unnecessary??.  46:381-381. 2004
• 15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer.  45:357-363. 2004
• Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline.  44:1-11. 2004
• Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.  43:223-240. 2004
• O-189 Practitioner feedback on lung cancer practice guidelines developed through cancer care Ontario's program in evidence-based care.  41:S56-S56. 2003
• O-193 The impact of practice guidelines and funding policies on the utilization and cost of chemotherapy in advanced non-small cell lung cancer (NSCLC): The experience from the province of Ontario, Canada.  41:S57-S57. 2003
• O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response.  41:S90-S90. 2003
• O-66 Impact of whole brain radiation therapy (WBRT) and motexafin gadolinium (MGd) on neurologic and neurocognitive progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase III trial.  41:S22-S22. 2003
• P-465 Differences in baseline characteristics between non-small cell lung cancer (NSCLC) and breast cancer (BrCa) patients with brain metastases.  41:S208-S209. 2003
• P-514 Can baseline quality of life parameters predict survival and other efficacy outcomes in malignant pleural mesothelioma?: Results from a 448-patient phase III trial.  41:S220-S220. 2003
• Phase II study of pegylated liposomal doxorubicin HCI (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.  41:S232-S232. 2003
• Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy.  39:1-13. 2003
• Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables.  37:235-240. 2002
• Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.  34:417-426. 2001
• Towards a biological staging model for operable non-small cell lung cancer.  34:S83-S89. 2001
• ALIMTA (TM) (pemetrexed, LY231514, MTA) in non-small cell lung cancer.  29:32. 2000
• Gemzar and Navelbine in the treatment of patients with stage III b and IV non-small cell lung cancer. A phase II trial.  29:31-31. 2000
• Pemetrexed (ALIMTA), a novel multitargeted antifolate agent, is active alone and in combination in thoracic tumors.  29:38-39. 2000
• Phase II trial of MTA (AlimtaTM) and cisplatin in patients with advanced Non-Small Cell Lung Cancer (NSCLC).  29:13-13. 2000
• Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.  29:169-177. 2000
• Taxotere in malignant pleural mesothelioma. A phase II clinical trial.  29:19-19. 2000
• An estimate of the cost of conducting phase II trials in lung cancer.  28:85-95. 2000
• Angiogenesis and non-small cell lung cancer.  27:81-100. 2000
• Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer.  23:19-30. 1999
• A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.  22:235-241. 1998
• 103 Multiple low dose chemotherapy agents for passive resistance in non-small cell lung cancer (NSCLC) and other malignancies. A pilot study.  18:29-29. 1997
• 168 A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC).  18:45-45. 1997
• 182 High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma.  18:49-49. 1997
• 183 Gemcitabine (G), VP16 (V) and cisplatin (P). Phase I study in small cell lung cancer (SCLC).  18:49-49. 1997
• 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study.  18:61-61. 1997
• 90 Comparison of the costs, toxicities, and inconvenience of different chemotherapy regimens for advanced non-small cell lung cancer.  18:26-26. 1997
• Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer.  18:83-94. 1997
• Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.  15:115-123. 1996
• The economics of lung cancer management in Canada.  14:19-29. 1996
• Adjuvant chemotherapy: results and perspectives.  12:S35-S45. 1995
• High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases.  11:251-258. 1994
• Rationale for the treatment of non-small cell lung cancer.  9:5-14. 1993
• Supportive care for patients with small cell lung cancer.  5:319-324. 1989
• The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report.  5:135-138. 1989
• Erratum to “The function of IGF-IR in NNK-mediated lung tumorigenesis” [Lung Cancer 71 (1) (2011) 11–18] - Lung Cancer 2016

has subject area

• 1103 Clinical Sciences (FoR)
• 1112 Oncology and Carcinogenesis (FoR)
• Oncology & Carcinogenesis (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0169-5002

Electronic International Standard Serial Number (EISSN)

• 1872-8332